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KEY POINTS
 Cancer therapy in exotic species is heavily reliant on extrapolation from treatment recom-
mendations for humans, dogs, and cats.
 The primary literature available for cancer in exotics is minimal and primarily comprises
single case reports or small case series.
 The basic principles of cancer treatment do not vary across species and should be
adhered to with modifications made for specific species requirements.
 Exotic clinicians should work closely with medical, surgical, and radiation oncologists to
ensure the best care for their patients.
 There is an urgent need for exotic clinicians to be more collaborative and share their cancer
cases to improve care for patients.INTRODUCTION
Treatment options for animals with cancer are rapidly expanding, including in exotic
animal medicine. Only limited information is available, however, about treatment
effects in exotic pet species beyond individual case reports. Consequently, most can-
cer treatment protocols in exotic animals are extrapolated from those described in
humans, dogs, and cats. Practical limitations, however, as well as anatomic or phys-
iologic differences can complicate the application of certain cancer treatment modal-
ities in exotic species. This review provides an overview and update on cancer
treatment in exotic animal species, including the various considerations that areThe authors have nothing to disclose.
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Zehnder et al466important during the initial diagnosis, therapeutic planning, and monitoring of the
exotic cancer patient.TUMOR STAGING
Signalment, history, and thorough physical examination are important parts of the
initial clinical evaluation of exotic patients with tumors. Because many tumors tend
to affect animals of a particular age, gender, or species, collection of this information
is vital. Diet history can help identify potential risk factors for neoplasia related to
malnutrition; for example, in epidemiologic studies, the intake of carotenoid-rich fruits
and vegetables has been correlated with protection from some forms of cancer1 and it
is suspected that chronic hypovitaminosis A may be a risk factor for development of
squamous cell carcinoma (SCC) in pet birds.2 Underlying viral disease is linked to
cancers in a variety of species, for example, cholangiocarcinoma in Amazon parrot
species with psittacid herpesvirus, lymphoproliferative disease in mice with murine
leukemia virus, fibropapillomas in sea turtles with herpesvirus, and walleye dermal sar-
coma retrovirus in fish, among others.3–6 Ultraviolet light radiation has been linked to
neoplastic disease in many species.7–9 Reproductive history is important because
chronic egg laying is a risk factor for development of ovarian/reproductive cancers.10
Previous infection with Macrorhabdus ornithogaster may increase the risk of proven-
tricular adenocarcinoma in budgerigars; therefore, a history of chronic macro rhabdio-
sis infection should not be overlooked.11 Additionally, any chronic nonhealing wound
or areas subject to repeated trauma or chronic inflammatory conditions may be at risk
for development of neoplasia. In addition to revealing risk factors for neoplastic
disease, patient evaluation is essential to determine the course of action. For example,
it is important to rule out underlying (and potentially zoonotic) disease, such as
chlamydiosis, salmonellosis, or mycobacteriosis, prior to the use of immunosuppres-
sive agents. Similarly, underlying metabolic disease, including renal or hepatic dis-
ease; heart disease, including atherosclerosis; and other organ dysfunction may
alter prognosis and a patient’s ability to tolerate treatment.
For any exotic species with a suspected tumor, histologic or cytologic diagnosis of
the tumor is recommended to determine (if possible) the tissue of origin and grade of
tumor. Cytology can help differentiate neoplastic from non-neoplastic lesions andmay
broadly indicate tumor type, but accurate histogenesis and tumor grading require
histology, with an exception of purely hematopoietic tumors, such as leukemias.12
Special stains, including immunohistochemistry, may be needed to further determine
various cellular antigens and cell of origin (discussed later). Mitotic index may can help
determine tumor grade, but there is no clear evidence from the exotic species litera-
ture that mitotic index is prognostic.
The TNM approach, developed by the World Health Organization, is used in
mammalian species to stage solid tumors and has been adapted for evaluation of
disseminated tumors, such as lymphoma.12 The TNM approach evaluates the primary
tumor (T), presence or absence of metastatic disease in local and regional lymph
nodes (N), and presence or absence of metastatic disease within the rest of the
body (M). For exotic species that lack lymph nodes (birds, reptiles, and fish), this
general concept can be adapted using a TM approach to evaluate tumors to best
determine extent of disease and determine treatment options (Fig. 1). Because there
is no clinical evidence to support the use of more precise tumor scales like those
developed for specific tumors in human and companion animals, the authors recom-
mend a more general staging technique that considers the overall health of the animal,
in addition to details about the primary tumor and metastatic lesions. Once additional
Fig. 1. Algorithm for TM tumor staging in exotic animal patients without lymph nodes.
(Adapted from Zehnder A, Graham J, Reavill DR, et al. Neoplastic diseases in avian species.
In: Speer B, editor. Current therapy in avian medicine and surgery. 1st edition. St Louis [MO]:
Elsevier; 2016. p. 114; with permission.)
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nosis based on tumors at their initial presentation can be made.
TM Approach
In evaluation of the primary tumor (T), the tumor is sampled by way of aspirates for
cytologic diagnosis or biopsy for histologic diagnosis. In some situations, complete
surgical excision of the mass may be the best option for diagnosis and treatment if dis-
ease is localized. The extent of the tumor can be evaluated by clinical examination of
the patient but disease may extend beyond visible margins. Diagnostic imaging tech-
niques, such as plain and contrast radiography, ultrasonography, CT, MRI, and endos-
copy, can help assess extent of the tumor, depending on the tumor site. Objective
tumor description, including specific location and measurement, in 3 planes whenever
possible, should be recorded to monitor patient response. Two recent publications
have provided avian body maps for use to describe more completely the location of
tumors,13,14 and maps for dogs and cats can often be adapted for many small
mammal species.
In evaluation for metastatic disease (M), although the lung can be a common site
for distant metastatic disease, other sites include the skin, liver, kidneys, bone,
brain/nervous tissue, and spleen.13 Physical examination may suggest metastases
Zehnder et al468(for example, cutaneous masses), but diagnostic imaging techniques, as described
previously, are generally required to evaluate for metastases. Multiple radiographic
views can help evaluate for metastatic disease but CT scan is generally more sensitive
for evaluation of metastatic disease compared with radiographs in many species. Ra-
diographs may show changes in the size of shape of the liver, spleen, lymph nodes,
and kidneys, but ultrasound-guided aspirates or endoscopic biopsies may be required
to determine extent of disease into these organs. Bone marrow aspiration is recom-
mended for staging and diagnosing disseminated diseases like lymphoma or leuke-
mia. More advanced imaging modalities, including MRI, PET scan, and technetium
(99mTc) bone scan, have been used to evaluate for metastatic disease in a variety of
species.13,15
CLINICAL PATHOLOGY
Complete Blood Cell Count
A complete blood cell count (CBC) should be performed as part of a minimum data-
base collection on any patient evaluated for cancer diagnosis or treatment. Anemia
or leukopenia could indicate bone marrow or splenic disease. Leukocytosis with a
neutrophilia or heterophilia with or without evidence of toxicity or a left shift may indi-
cate a concurrent infection or infection related to the tumor itself, and appropriate anti-
biotic therapy should be instituted based on the site of the infection (if known) and,
ideally, culture and sensitivity. Chemotherapy agents are generally most toxic to
rapidly dividing cells so toxicity to the bone marrow and gastrointestinal (GI) tract is
a concern. CBCs should be monitored and treatment should be delayed if the hetero-
phil or neutrophil count is too low, that is, less than 2000 cells/mL, as recommended in
dogs and cats.15,16
Biochemistry
Similar to CBC, biochemistry profile is recommended as part a minimum database
collection. Renal or hepatic enzyme elevation may indicate organ involvement or
dysfunction and may preclude use of certain chemotherapeutic drugs. Nevertheless,
these tests rarely provide definitive information as to the type of cancer or whether
metastasis is present.
IMAGING MODALITIES
Imaging often is essential in determining both the resectability of a primary tumor as
well as identification of suspected metastatic lesions. This information is crucial for
devising a rational treatment plan for a veterinary cancer patient. Radiographs of
the thorax are valuable in determining the clinical stage of disease in mammals. To
assess the lungs properly in mammals, 3 views should be obtained—both left and
right lateral views as well as a ventrodorsal view, and these recommendations can
be helpful for nonmammalian exotic patients as well. Conventional radiography, pref-
erably with high-detail film, may provide adequate diagnostic imaging for nasal and
oral tumors, although the extent of disease may not be fully elucidated. Ultrasonogra-
phy allows evaluation of the architecture of abdominal viscera and has largely
replaced radiographs in staging of mammalian cancer patients with abdominal
neoplasia. CT has become more widely available for veterinary use, particularly at
teaching institutions and large specialty practices. CT can be helpful to evaluate tu-
mors within the nasal and oral cavities. CT is particularly useful when a veterinarian
is trying to determine tumor margins prior to surgery or radiation therapy. CT imaging
of the lungs, often accomplished with controlled ventilation, provides increased
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lesion location17,18 compared with traditional radiography.
MRI is often the modality of choice for imaging tumors of the brain and spine.
Lesions of the brainstem may require MRI for diagnostic quality. In addition to CT,
MRI is useful when a veterinarian is trying to determine tumor margins prior to surgery
or radiation therapy. MRI is often considered more sensitive in detecting tumor mar-
gins in soft tissues. Due to the slow speed of image acquisition, MRI has limited utility
in imaging of the thorax in mammals and birds due to movement of the heart and
lungs. PET is used to stage, plan surgery, evaluate response to therapy, and detect
relapse of various neoplastic conditions. PET has been used to evaluate 2 cases of
avian neoplasia, and normal PET image acquisition in Hispaniolan Amazon parrots
has been described.19
TREATMENT MODALITIES
Although there are abundant articles on toxicity of chemotherapeutic agents in labo-
ratory animals, these studies are generally performed in healthy animals at nonthera-
peutic doses in a laboratory setting and can be hard to extrapolate to pet species.
Because information regarding the treatment effects in exotic pet species is scarce
and generally limited to individual case reports, cancer treatment protocols in exotic
animals are generally extrapolated from those described in humans, dogs, and cats.
There are some important differences, however, between exotic species versus dog
and cat patients. Notably, many exotic patients presenting with tumors are small and
vascular access is challenging for intravenous administration of chemotherapeutics.
Nevertheless, the use of vascular access ports has been reported in exotic species,
including ferrets, birds, rabbits, rodents, and reptiles, and can be considered
in situations where repeated vascular access is necessary (eg, to administer medica-
tion or sample blood to monitor systemic response to therapy [Fig. 2]).15,20 Due to their
small size, vascular access ports in exotic patients are prone to clotting, and appro-
priate heparin locking is required to maintain function.
Depending on the type of neoplasia, a variety of treatment modalities can be consid-
ered for exotic species. Oral chemotherapeutics used in humans, dogs, and cats can
be used in exotic animals, but compounding into appropriate doses may be neces-
sary. If a medication needs to be swallowed whole versus crushed, use in exoticFig. 2. Vascular access port placement in a wolf with a myxosarcoma. (Courtesy of Tara Harrison,
DVM, MPVM, DACZM, DACVPM, North Carolina State University).
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plastic drugs into the tumor and nearby tissue and can be used in combination with
surgery or radiation therapy. Slow-release formulations, such as sesame oil emulsions
or collagen matrix, can optimize pharmacokinetics to allow for more prolonged expo-
sure of the drug to tissue.
Radiation therapy is a common treatment modality in some exotic animal tu-
mors, including thymoma in rabbits. Radiation therapies available for use in veter-
inary patients include teletherapy, plesiotherapy, brachytherapy, and systemic
radiation therapy with radionucleotides.21 In some situations, radiation therapy is
combined with surgery or chemotherapy to maximize the chance for tumor
response to therapy. Hormonal therapy, phototherapy, hyperthermia, immuno-
therapy, nonsteroidal therapy, antiangiogenic antibiotics, metronomic chemo-
therapy, and complementary and alternative therapy are other considerations for
treatment of exotic neoplasia.TRANSLATING CANCER THERAPIES TO EXOTICS
Metabolism
Birds have a high metabolic rate compared with most mammals but pharmacokinetic
data has been obtained with some chemotherapeutics in a limited number of avian
species. Results of these studies show that extrapolation of dosing regimens from
mammals to avian species is at least a good starting point.22 The opposite may be
true for reptiles, and doses may need to be reduced or dosing intervals made less
frequent as for other types of medications, such as antibiotics. Studies to determine
appropriate metabolic scaling of chemotherapeutics for reptiles are, however,
lacking. For poikilotherms, the ambient temperature and availability of appropriate
temperature gradients within the enclosure are important for adequate drug meta-
bolism. Better information is available in the laboratory animal literature for small
mammals, but doses and dose intervals often still need to be adjusted from dog
and cat doses.
Vascular Support, Renal/Hepatic Excretion
Birds and reptiles have a renal portal system and, in general, injection of chemother-
apeutic drugs into leg vasculature should be avoided to prevent excretion of these
agents before they enter the full circulatory system. Additionally, caution should be
taken with the injection of any nephrotoxic agents into the leg vasculature for the
same reason.
Risks of Corticosteroids and Immunosuppressive Agents
Any immunosuppressive therapy should be used with caution in most exotic species.
Because of the high number of zoonotic diseases reported in exotic species, this issue
must be taken into consideration when using immunosuppressive therapy in these
patients or if owners are immunocompromised. Steroid therapy is not without risk
of immunosuppression and secondary infection in exotic patients. Prophylactic
antibiotic and antifungal therapy may be prudent whenever immunosuppressive drugs
are used in these species. Certain species are known to harbor chronic infections that
can exacerbate, flare up, or manifest clinically after use of steroids (eg, Escherichia
cuniculi infections in rabbits). Thus, care should be taken before starting steroids in
any exotic species. The exception to this is ferrets, which seem to tolerate steroid ther-
apy well, and steroids can be used to help manage common diseases, like GI
lymphoma.23,24
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Although the use of chemotherapy in exotic animal oncology is increasing, the infor-
mation in literature is limited and mainly based on case study findings and extrapola-
tion from the human literature and the treatment of dogs and cats. Dosing of
antineoplastic drugs should be done carefully because of their narrow therapeutic-
toxic range. Therefore, it is of great importance to understand the basic mechanisms
of action and potential toxicities before attempting to treat any animal species with
chemotherapy (Table 1). Because recent reviews have discussed the basic pharma-
cology of common chemotherapeutics, this point is not be belabored in this article.20
Currently, there is a growing interest in combining anticancer drugs aiming at maxi-
mizing efficacy while minimizing systemic toxicity through the delivery of lower drug
doses. Combining 2 or more agents has a greater response than when used alone.
The development of a multiagent chemotherapy protocol is based on selecting agents
that act at different phases of the cell cycle (Fig. 3), have independent mode of ac-
tions, have synergistic effects to overcome drug resistance, and vary in their toxicities.
Chemotherapy drugs can be administered by multiple routes, including orally, subcu-
taneously, intralesionally, intravenously, and intraosseously (Fig. 4). In particular,
repeated intravenous administration might be difficult in many exotic animal species
because of limited vascular access and because of the high vesicant and irritant prop-
erties of many chemotherapy drugs. In human medicine, there is a major trend in the
development of oral chemotherapy, driven by pharmacoeconomic issues as well as
patient convenience and quality of life. The availability of more oral chemotherapeutics
will facilitate future usage of chemotherapy in exotic animals. Regardless of the route
chosen, clinicians administering chemotherapy need to take appropriate precautions
to protect themselves, patients, and owners from contact with potential toxic chemo-
therapeutics (Fig. 5).20
Chemotherapeutics are commonly dosed based on the body surface area (BSA) of
a patient instead of the bodyweight (BW), because the BSA is considered a better
indicator of the metabolic mass.77 Because knowledge in exotic animal cancer treat-
ment is limited, the use of BSA to derive interspecies equivalents for therapeutic dos-
ages is opening treatment perspectives. Misunderstood and misinterpreted use of
BSA conversions, however, may have unfavorable consequences, including under-
dosing, leading to treatment failure, and overdosing, inducing unexpected severe or
even deadly adverse effects. Therefore, dose extrapolation between different animal
species should be based on more advanced allometric and physiologically based
pharmacokinetic modeling.146 Recently, Antonissen and colleagues22 demonstrated
by allometric scaling a clear correlation (R2>0.97) between BW and the elimination
half-life (T1/2el) of carboplatin in different avian species, expressed by the formula,
T1/2el carboplatin 5 0.1147 (log value of BW)
0.3046. T1/2el could also be scaled with an
acceptable correlation (R2 5 0.83) in different mammalian species (rats, cats, dogs,
and humans)147–150 and different avian species (budgerigar, pigeons, ducks, cocka-
toos, and chickens).22,137 Allometric scaling within 1 animal class is, however,
preferred. Furthermore, carboplatin clearance is highly correlated with the animals’
glomerular filtration rate. Taking into account the enormous differences in physiology
between different exotic animal species, interanimal class dose extrapolation of che-
motherapeutics is related to a major risk of therapy failure.
EMERGING MOLECULARLY TARGETED AGENTS
Most traditional chemotherapeutics have been drugs or other therapies that target
cancer cells by killing rapidly dividing cells or killing all the cells in a particular area
Table 1
Chemotherapy agents that can be used in exotic animal medicine
Chemotherapy
Agent
Mode of
Action/Pharmacokinetics
Principal
Indications
Toxicities/Side
Effects
Administration
Routes Dosage Case Reports
Nitrosoureas  Highly lipophilic, which enter cells
through passive diffusion
 Undergo bioactivation by cytochrome
P450 enzymes in the liver
 These metabolites cause alkylation and
cross-linking of DNA (at the O6-posi-
tion of guanine-containing bases) and
RNA, thus inducing cytotoxicity.
 Also inhibit several key processes, such
as carbamoylation and modification of
cellular proteins
 Urinary excretion, with minimal biliary
excretion and GI reabsorption
 Cell-cycle nonspecific
Lomustine
(CCNU)
 Lymphoma
 Mass cell tumor
 Histiocytic
sarcoma
 Brain tumor
 Myelosuppression
 GI toxicity
 Sores in oral cavity
 Pulmonary toxicity
 Renal toxicity
 Hepatotoxicity
PO 30–90 mg/m2
Interval 3–8 wk30–32
20,25–29
Carmustine
(BCNU)
 Lymphoma
 Neurologic
tumor
 Myelosuppression
 Pulmonary toxicity
 GI toxicity
IV, local
delivery
50 mg/m2
Interval 6 wk33,34
N/A
Nitrogen
mustard
alkylating
agents
 Bifunctional alkylating agents
 Mustards react with the N7 atom of
purine bases, especially when they are
flanked by adjacent guanines,
inducing DNA strand breakage, cross-
linking strands of DNA and ring
cleavage.
 Cell-cycle nonspecific
 Well absorbed after PO administration
 Excretion: small fraction a dose elimi-
nated unchanged by urinary excretion,
with minimal biliary excretion, major-
ity eliminated by metabolic
transformation35–37
 Cyclophosphamide and ifosfamide:
parent drug is relatively inactive, un-
dergo bioactivation via hydroxylation
by cytochrome P450 enzymes in the
liver with formation of (iso)phosphor-
amide mustard
 Chlorambucil and melphalan: direct
alkylating ability
 Sensitive to acquired tumor cell resis-
tance by increased gluthatione
conjugation38
Cyclophosphamide  Lymphoma
 Carcinoma
 Sarcoma
 Myelosuppression39
 GI toxicity
 Renal toxicity
 Urothelial toxicity
(1 furosemide,48 mesna49)
 Feather abnormalities51
PO, IV, IO 10–80 mg/m2 PO
3–4 consecutive d/wk40,46,47
100–200 mg/m2 IV, IO
Interval 1–3 wk
15 mg/m2 PO daily
(metronomic)47,50
20,40–45
Ifosfamide  Lymphoma
 Sarcoma
 Myelosuppression
 GI toxicity
 Renal toxicity
 Urothelial toxicity
(1 furosemide,54 mesna55)
 Neurotoxicity
PO, IV 375–900 mg/m2 IV
Interval 3–4 wk52,53
N/A
Chlorambucil  Lymphocytic
leukemia
 Lymphoma
 Mast cell tumor
 Myeloma
 Ovarian
adenocarcinoma
 Myelosuppression
 GI toxicity
 Renal toxicity
 Hepatotoxicity
 Pulmonary toxicity
 Alopecia
PO 10–20 mg/m2 or 1–2 mg/kg
Interval 0.5–2 wk56,61
4 mg/m2 PO daily
metronomic62,63
26,40,42,56–60
Melphalan  Myeloma
 Lymphocytic
leukemia
 Lymphoma
 Ovarian
adenocarcinoma
 Myelosuppression64
 GI toxicity
 Pulmonary toxicity
PO 0.1 mg/kg daily for 10 d
followed by 0.05 mg/kg
per day or pulse dose
administration of
3–7 mg/m2 for
5 d in 3-wk cycle65–67
65
4
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Antitumor
antibiotics
Anthracyclines and anthracenediones:
 Drugs first extracted from Strepto-
myces spp
 Intercalation into DNA and disruption
of topoisomerase-II–mediated DNA
repair
 Iron-mediated generation of free oxy-
gen radicals that damage the DNA,
proteins, and cell membranes
 Cell-cycle nonspecific, although maxi-
mally cytotoxic during S phase
 Low oral bioavailability
 Doxorubicin is metabolized extensively
to doxorubicinol by the ubiquitous
aldo-keto reductase enzymes; by
interfering with the iron and calcium
regulation, this metabolite is impor-
tant for doxorubicin cardiotoxicity.68,69
 Biliary excretion, with minimal urinary
excretion
Doxorubicin  Lymphoma
 Sarcoma
 Carcinoma
 Cardiotoxicity72
 Myelosuppression
 GI toxicity
 Renal toxicity
 Hypersensitivity
(mainly GI and
skin related)
 Alopecia
 Perivascular damage
with extravasation
IV, IO 20–60 mg/m2 or 1–2 mg/kg
Interval 2–3 wk77–80
20,40,41,43,68,73–76
Epirubicin  Lymphoma
 Sarcoma
 Carcinoma
 Less cardiotoxic than
doxorubicin81,82
 Similar to doxorubicin
IV 30 mg/m2
Interval 3 wk83
N/A
Mitoxantrone  Lymphoma
 Sarcoma
 Carcinoma
 Less cardiotoxic than
doxorubicin
 More hepatotoxic than
doxorubicin87
 Myelosupression
 GI toxicity
IV, local
delivery84–86
2.5–5 mg/m2 IV
Interval 3 wk88,89
N/A
Chromomycins:
 Drug first extracted from Streptomyces
spp
 Inhibit RNA synthesis by binding to
guanine residues and inhibiting DNA-
dependent RNA polymerase
 Intercalation into DNA and disruption
of topoisomerase-I and topoisomerase-
II–mediated DNA repair70
 Cell-cycle nonspecific
 Biliary excretion, with minimal urinary
excretion
Actinomycin D
or dactinomycin
 Lymphoma  Myelosuppression
 GI toxicity
 Perivascular damage with
extravasation
IV 0.5–0.8 mg/m2
Interval 3 wk90,91
N/A
Miscellaneous:
 Drug first extracted from Streptomyces
spp
 Forming an iron-oxygen-bleomycin
complex that then forms free radicals,
which cause single and double-
stranded DNA breaks
 Cell-cycle specific (G2 and M phase)
Bleomycin  Lymphoma
 Fibropapiloma
 SCC
 Pulmonary toxicity
 Stomatitis
 Hyperpigmentation of
skin
 Hypersensitivity
IV, IM, SC,
local delivery
10–20 U/m2 for 3–9 d,
then weekly
20,92,93
(continued on next page)
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Table 1
(continued )
Chemotherapy
Agent
Mode of
Action/Pharmacokinetics
Principal
Indications
Toxicities/Side
Effects
Administration
Routes Dosage Case Reports
 Metabolized by a cysteine protease
hydrolase enzyme in normal tissues.
The enzyme replaces a terminal amine
with a hydroxyl, thereby inhibiting
iron binding and cytotoxic activity. The
low enzyme concentration in skin and
lung may explain the unique sensitivity
of these tissues to bleomycin toxicity.71
 Mainly excreted with urine
Antitubulin
agents
Vinca alkaloids
 Vincristine and vinblastine first ex-
tracted from periwinkle plant (Cathar-
anthus rosea); vindesine and
vinorelbine are semisynthetic deriva-
tives of vinblastine.
 Bind to the free tubulin-dimers, inhib-
iting the formation of microtubule—
more specifically, the forming of the
mitotic spindles—and thereby mitosis
 Cell-cycle phase specific (M phase)
 Metabolized in liver by cytochrome
P450, and concomitantly administered
drugs may either competitively inhibit
or induce cytochrome P450 clearance
of vinca alkaloids.
 Largely excreted in the bile and feces,
with little renal excretion94,95
Vincristine  Lymphoma
 Mast cell tumor
 GI toxicity
 Myelosuppression
 Neurotoxicity
 Perivascular vesicant
 Alopecia
IV, IO, local
delivery
0.1–0.75 mg/m2
Interval 1–2 wk
20,40,41,43,44,57,101,102
Vinblastine  Mast cell tumor103
 TCC104
 GI toxicity
 Myelosuppression
 Perivascular vesicant
IV 2.0–3.5 mg/m2
Interval 1–2 wk103,147
Vinorelbine  Lymphoma
 Mast cell tumor
 TCC
 Histiocytic
sarcoma
 Pulmonary
carcinoma
 Myelosuppression
 Perivascular vesicant105
 Less neurotoxic
than vincristine
IV 15 mg/m2
Interval 1–2 wk105,107,108
105,106
Taxanes
 Complex diterpenes (hydrocarbons)
originally identified from plants of the
genus Taxus (yews)
 As opposed to vinca alkaloids, taxanes
increase microtubule stability and pre-
vent dipolymerization, which causes
tubulin bundling.
 Cell-cycle phase specific, cells are ar-
rested in G2/M phase, which is known
to be the most radiosensitive phase of
the cell cycle.
Paclitaxel  Carcinoma
 Sarcoma
 Myelosuppression
 Hypersensitivity
 Neurotoxicity
 Alopecia
 GI toxicity
IV, PO 130–150 mg/m2 IV
Interval 3 wk96,109
N/A
Docetaxel  Carcinoma
 Sarcoma
 Myelosuppression
 Hypersensitivity
 GI toxicity
IV, PO 20–30 mg/m2 or
1–2.5 mg/kg IV
Interval 3 wk111,112
110
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 Widely distribute into most tissues,
except central nervous system
 Substrates for the P-glycoprotein
transporters, which interfere with their
GI absorption—novel taxane analogs
have been developed in human medi-
cine that are poor substrates for
P-glycoprotein and have higher oral
bioavailability,96 or taxane oral
bioavailability increases by coadminis-
tration of competitive substrates for
example, cyclosporine A.97
 Largely excreted in the bile and feces,
with little renal excretion
Topoisomerase interactive agents
 Semisynthetic derivatives of
podophyllotoxin
 Inhibit DNA synthesis by forming a
complex with topoisomerase-II and
DNA. This complex induces break in
double-stranded DNA and prevents
repair by topoisomerase-II binding.
 Cell-cycle phase specific (late G2 and
early S phases)
 Oral bioavailability is highly variable.
Substrates for the P-glycoprotein
transporters, which interfere with their
GI absorption—oral bioavailability in-
creases by coadministration of
competitive substrates, for example,
cyclosporine A.98,99
 Converted to an O-demethylated
metabolite by hepatic microsomal cy-
tochrome P450, which has a similar
potency at inhibiting topoisomerase-II
and is more oxidatively reactive than
the parent drug.100
 Mainly excreted with urine
Etoposide  Hemangiosarcoma113
 Osteosarcoma115
 Lymphoma114
 Lung carcinoma
 Myelosuppress n
 Hypersensitivit
 GI toxicity
 Cardiotoxicity
IV, PO 50 mg/m2 PO daily
for 3 wk, 25 mg/m2 for 4
consecutive days IV113,114
N/A
Teniposide  Leukemia
 Lymphoma
 Lung carcinoma
 Myelosuppress n
 Hypersensitivit
 GI toxicity
 Cardiotoxicity
IV, PO 20 mg/kg IV or PO single
administration
6.5 mg/kg IV
Interval 3 d116,117
N/A
(continued on next page)
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Chemotherapy
Agent
Mode of
Action/Pharmacokinetics
Principal
Indications
Toxicities/Side
Effects
Administration
Routes Dosage Case Reports
Antimetabolites General
 Similar to endogenous metabolites,
which are needed for normal
biochemical activities involved in
normal cell function and replication
 Interfere directly with normal cell
metabolism, interacting directly with
specific enzymes by either inhibiting
enzyme production or by producing a
nonfunctional end product blocking
cell processes dependent on that
enzyme or end product, inhibiting
protein, RNA or DNA synthesis
 Cell-cycle phase specific
(S phases)
Pyrimidine antagonists
 Analogs of uracil or cytosine
 5-Fluoropyrimidines are structural py-
rimidine base analog of uracil, inhibit-
ing the enzymatic conversion of uracil
to thymidine, inducing failure of
normal DNA synthesis, faulty transla-
tion of RNA, and finally cytotoxicity of
the rapidly dividing cancer cells.
 Clearance of 5-fluoropyrimidines
mediated by cytosolic enzyme dehy-
dropyrimidine dehydrogenase–satu-
rable process: impact on efficacy and
safety bolus vs infusion administration
 Gemcitabine is activated by being tri-
phosphorylated on transport into the
cell, which is catalyzed by the enzyme
deoxycytidine kinase. Triphosporylated
gemcitabine can masquerade as cyti-
dine and is incorporated into new DNA
strands. By masked chain termination
5-Flurouracil  Carcinoma  Myelosuppression
 GI toxicity
 Cardiotoxicity124,125
 Neurotoxicity
IV, local delivery 150–200 mg/m2 IV
Interval 1 wk123
1.47 mg/kg intralesionally
Interval 3 wk121,122
121,122
Gemcitabine  Lymphoma
 Carincoma
 Myelosuppression
 GI toxicity
IV 275–400 mg/m2
Interval 2–3 wk
Low dosage of 40 mg/m2 as
radiosensitizer118,126
20
Cytarabine  Lymphoma
 Leukemia
 Myelosuppression
 GI toxicity
IV, SC 100–150 mg/m2 IV or SQ for 4–5
consequent days
repeat interval 3–4 wk127,128
44,127
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by a normal nucleoside base aside
gemcitabine, normal cell repair system
not activated. Consequently, due to
this irreparable DNA error, further DNA
synthesis is inhibited and leads to cell
death.118
 Cytosine arabinoside or cytarabine is a
deoxycytidine base compound, which
is phosphorylated in cells to the active
metabolite arabinosylcytosine triphos-
phate, which is a competitive inhibitor
of DNA polymerase a, and is incorpo-
rated into DNA and causes strand
termination. Consequently, the cancer
cell is unable to divide.119
 Low oral bioavailability
 Mainly excreted with urine120
Folate antagonist
 Methotrexate is a competitive inhibi-
tor of the enzyme folic acid reductase,
preventing reduction of dihydrofolate
to tetrahydrofolate, which is necessary
for the synthesis of thymidylate, an
essential component of DNA.119
 High oral bioavailability
 Largely excreted by urine but also
substantial biliary excretion
Methotrexate  Lymphoma  Myelosuppression
 GI toxicity
PO, IV 2,5–5,0 mg/m2 PO
Interval 1–2 d123
0.3–0.8 mg/m2 IV
Interval 1–3 wk
40
Corticosteroids  Induce apoptosis of hematopoietic
cancer cell by interaction with gluco-
corticoid receptor
 Inhibit inflammatory and immune re-
sponses, most likely through alteration
of cellular transcription and protein
synthesis as well as through effects on
lipocortins, which inhibit the release of
arachidonic acid
 Provide palliative appetite and anti-
inflammatory support
 Very high oral bioavailability
Prednisolone/
prednisone
 Lymphoma
 Mast cell tumor
 Leukemia
 Brain tumor
 Insulinoma
 Polyuria/polydipsia
 Polyphagia
 GI toxicity
 Hepatotoxicity
 Hyperadrenocorticism
 Dull hair coat
 Pancreatitis
PO 0.5–2 mg/kg BW PO daily 20,26,41–44,58,76
(continued on next page)
4
7
7
Table 1
(continued )
Chemotherapy
Agent
Mode of
Action/Pharmacokinetics
Principal
Indications
Toxicities/Side
Effects
Administration
Routes Dosage Case Reports
 Avian patients: long-term usage pre-
disposing for aspergillus infection or
severe immune suppression
 Do no use in combination with NSAIDs:
increased toxicity
 Cell-cycle nonspecific
Platinum  Binding covalently to the N7 position
of the imidazole ring of the purine
bases of DNA, primarily guanine, and
to a lesser extent adenine, forming
monofunctional or bifunctional DNA
intrastrand and interstrand adducts.
This activates various signal-transduc-
tion pathways, such as those involved
in DNA damage recognition and repair,
cell-cycle arrest, and programmed cell
death/apoptosis.129
 Platinum drugs (II), such as cisplatin,
carboplatin, and oxaliplatin, are not
orally bioavailable due to their chemi-
cal reactivity, poor absorption, and se-
vere GI side effects.
 Platinum (IV) compounds, such as sa-
traplatin and tetraplatin, can be
administered orally. These platinum
compounds are prodrugs; once they
enter cancer cells, they are reduced
and activated by cellular reductants
and form active complexes. These
compounds are still under
investigation.130
 Mainly excreted with urine—platinum
drug clearance is strongly associated
with glomerular filtration rate. Carbo-
platin dosing using a pharmacologic
formula is based on glomerular filtra-
tion rate and produces accurate tar-
geting of the carboplatin AUC.131
 Cell-cycle nonspecific
Cisplatin  Carcinoma
 Sarcoma
 Myelosuppression
 GI toxicity
 Nephrotoxicity
 Ototoxicity
 Pulmonary edema
(species-specific,
demonstrated in cats)136
IV, IO, local
delivery
70 mg/m2 IV
Or 1 mg/kg BW IV
Interval 3 wk134
1 mg/cm3 intratumoral135
20,132,133
Carboplatin  Carcinoma
 Sarcoma
 Myelosuppression
 GI toxicity
 Less neurotoxic/
ototoxic than cisplatin142
IV, IO, local
delivery
125–300 mg/m2 IV
Or 5–10 mg/kg BW IV22,137
Interval 3 wk
1.5 mg/cm3 intratumoral143
20,22,74,137–141
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L-Asparginase  Enzyme purified from the bacterium E
coli or Erwinia carotovora
 Asparaginase hydrolyzes L-asparagine
to L-aspartic acid and ammonia in
leukemic cells, resulting in depletion of
asparagine, inhibition of protein syn-
thesis. Asparagine is critical to protein
synthesis in leukemic cells, because
these cells lack the enzyme asparagine
synthase.
 Pegaspargase: polyethylene glycol-
conjugated asparaginase is slow-
release form of E coli asparaginase
 L-Asparaginase resistance in tumor
cells, for example, by development of
antiasparginase antibodies, or de novo
biosynthesis of aspargine
 No antigenic cross-reactivity between E
coli and E carotovora asparaginase
 No oral administration: denaturation
and peptidase digestion within GI tract
 Cell-cycle specific (G1 phase)119
L-Asparginase  Lymphoma
 Leukemia
 Hypersensitivity144
 GI toxicity
 Coagulopathies
 Pancreatitis
 Hepatotoxicity
 Hyperglycemia
IM, SC 400 IU/kg BW IM/SQ
Or 10,000–12,000 IU/m2
Weekly interval
20,26,58
Hydroxyurea  Inhibits DNA synthesis by inhibition of
ribonucleotide diphosphate reductase.
Hydroxyurea inhibits the conversion of
DNA bases by blocking ribonucleotide
reductase, thereby preventing conver-
sion of ribonucleotides to
deoxyribonucleotides.
 Hydroxyurea also inhibits the incorpo-
ration of thymidine into DNA and may
directly damage DNA.
 Well absorbed after oral
administration
 Largely excreted by urine
 Cell-cycle specific (S phase)
Hydroxyurea  Leukemia
 Mast cell tumor
 Meningioma
 Myelosuppression
 GI toxicity
PO 30–60 mg/kg daily145 N/A
Abbreviations: IO, intraosseous; IV, intravenous; PO, oral; SC subcutaneous; N/A, Not Reported.
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Fig. 3. Cell-cycle specific and cell-cycle nonspecific chemotherapeutic agents. Multiagent
chemotherapy protocols should be based on selecting agents that act in at different phases
of the cell cycle.
480 Zehnder et alof the body affected by cancer. Although these treatments have certainly helped cure
many patients, they also frequently have treatment-limiting side effects due to effects
on normal cells. The holy grail of cancer therapy is to kill a cancerous cell while leaving
Fig. 4. Intralesional carboplatin administration to SCC in a cockatiel.
Update on Cancer Treatment in Exotics 481normal, healthy cells intact. New generations of targeted therapies attempt to achieve
this goal through logically designed therapies targeting cancer specific mutations or
cancer-specific pathways (Fig. 6 and Table 2). Although many targeted agents actu-
ally affect many different receptors, with targeted therapies it becomes more impor-
tant to know which particular mutations are present in a cancer cell or which
cellular pathways it depends on for survival to rationally guide treatment. Although
these therapies hold a great deal of promise for offering new, potentially less toxic
treatments for exotic patients, it is unclear to what extent tumors in exotic species ex-
press the cellular receptors targeted by these agents. This may make it more difficult
to translate new therapies emerging in human medicine (and for dogs and cats)
without knowing how cancers in exotic species are alike and different. Some clinicians
have begun to provide these therapies to patients when there are no other acceptable
treatment options, but results from these cases are not yet available. These drugs also
can have significant toxicities (see Table 2). Also, information on appropriate dosing
for therapeutic efficacy is not at all known, and owners should always be made aware
that use of these therapies in exotic species is experimental. Recording standardizedFig. 5. Safety measures in handling chemotherapy: intravenous administration of carbopla-
tin in a chicken. Veterinarians administering chemotherapy need to be familiar with the
chemotherapeutic agents used and of safety issues for themselves, owners, and staff.
Luer-Lok syringes should be used to avoid drug leakage, and all personnel handling drugs
or patients receiving chemotherapeutic drugs should wear protective clothing, including
gloves, eye protection, closed-toe shoes, and long sleeves.
Fig. 6. Schematic of molecular targets for cancer therapy. A, antibody against cell surface
receptor. B, cell surface receptor. C, small molecular inhibitor of cell surface receptor. D in-
hibitor of downstream pathway components. E, inhibitor of gene fusion product. (Adapted
from Zehnder A, Graham J, Reavill DR, et al. Neoplastic diseases in avian species. In: Speer B,
editor. Current therapy in avian medicine and surgery. 1st edition. St Louis [MO]: Elsevier;
2016. p. 132; with permission.)
Zehnder et al482case parameters (adverse effects and outcome information) for cases in which these
agents are used is critical to evaluate their potential use in exotics species.
The types of therapies being developed for use in human and companion animals
are summarized later and in Table 2, so that clinicians are aware of the types of ther-
apies that may be available for treating exotic patients, with the caveat that little is
known about the underlying cancer biology or the expression of certain cellular recep-
tors in exotic species.
Tyrosine Kinase Inhibitors
There are 2 tyrosine kinase inhibitors that have been used in veterinary patients. Tyro-
sine kinases are cellular receptors that help normal cells and cancer cells interact with
extracellular signals and are often mutated or overexpressed in multiple cancer types.
The first is toceranib phosphate (Palladia), an inhibitor of the split-kinase family, which
includes several growth factors implicated in cancer development: vascular endothe-
lial growth factor receptor, platelet-derived growth factor receptor, c-kit, Flt-3, and
others.183 It was originally developed for use in mast cell tumors with an activating
c-kit mutation but its role as an antiangiogenic therapy is also being studied, due to
its inhibition of additional kinase family members. Toceranib has been used in a bin-
turong (Actictis binturong) with renal carcinoma after nephrectomy with no discernible
clinical effect but minimal adverse effects (mild inappetence).184 In dogs, toceranib
has been evaluated for safety in patients with a variety of solid tumor types185 and
found generally safe, with some mild GI effects requiring a treatment holiday. Re-
ported side effects, however, can be as severe as GI perforation and can include other
manifestations, such as lameness, hematochezia, pruritus, and localized edema (in a
radiation patient).
Table 2
Summary of molecularly targeted agents
Toceranib
Combined with Species N Tumor Type(s) Clinical Effects Adverse Events Study Type Citation
Dogs 57 Various (MCT, lymphoma,
STS, MMC, TCC,
melanoma, OSCC, others)
ORR: 28% (highest in—
55%)
Appetite loss, diarrhea,
vomiting, neutropenia,
grades 1 and 2, seen with
daily dosing
Experimental,
prospective, phase I
151
Single agent Dogs 40 STS, TC, ASAGACA, NCA,
SCC, OSA, carcinoma
(various)
Clinical benefit: 90% Majority grades 1 and 2,
majority GI (52.5%),
hematologic (42.5%),
other effects:
hypertension, PLN,
lameness,
Experimental,
prospective (phase I—
evaluating effect of
lower dose)
152
Prednisone/
hypofractionated
radiation
Dogs 17 MCT ORR: 86.7%, CR: 66.7% GI and hepatic most
common, mostly grades 1
and 2
Experimental,
prospective clinical
trial
153
Vinblastine Dogs 14 MCT ORR: 71% Higher-grade neutropenia
with combination than
expected with single
agent, improved with
lower vinblastine doses
Experimental,
prospective phase I
clinical trial
154
Carboplatin/
cyclophosphamide
Dogs 126 OSA No significant survival
benefit
Grades 1 and 2 neutropenia
and thrombocytopenia,
trade 1 diarrhea, lethargy,
vomiting most common
Experimental,
prospective
(randomized clinical
trial)
155
Doxorubicin Dogs 43 HSA No significant survival
benefit (compared with
historical controls)
Grades 1 and 2 GI and
grade 1 anemia most
common
Experimental,
prospective
156
Cyclophosphamide Dogs 15 OSA, STS, HSA, LSA, MH,
TCC, TC, ASAGACA,
maxillary and perineum
carcinoma
Decreased circulating Treg
cells, increased serum
concentration of IFN-g
Grades 1 and 2, GI most
common
Experimental,
prospective
47
(continued on next page)
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Table 2
(continued )
Toceranib
Combined with Species N Tumor Type(s) Clinical Effects Adverse Events Study Type Citation
CCNU Dogs 13 Multicentric LSA, OSA, PCA,
STS, MLO, carcinoma/
adenocarcinoma
(various)
Clinical benefit: 53.8% Grades 3 or 4 effects:
neutropenia, elevated
ALT. AE more common in
higher CCNU dose
cohorts
Experimental,
prospective (phase I—
CCNU dose
escalation)
157
Lomustine Dogs 47 MCT ORR: 46% (not increased
over single agent
studies)
Grades 1 and 2 GI, anemia,
neutropenia most
common, grade 4
neutropenia (n 5 9)
Experimental,
prospective (phase I—
lomustine dose
escalation)
158
Vinblastine Dogs 10 TCC No significant response
(compared with historical
single agent studies)
Experimental,
prospective (pilot
study, no internal
control group)
159
Various Dogs 85 ASAGACA, OSA, TC, HNCA,
NCA
Clinical benefit: ASAGACA
(87.5%), OSA (47.8%), TC
(80%), HNCA (75%), NCA
(71.4%)
AE in 77.6%, majority GI
(AE not graded)
Observational,
retrospective
160
Prednisone Dogs 1 Chronic monocytic
leukemia
Clinical remission Not reported Case report 161
Piroxicam or
meloxicam
Cats 46 FOSCC Significant increased
survival rate compared
with NSAID only controls
Grades 1 and 2 lethargy,
anorexia, vomiting most
common
Cohort, retrospective 162
Prednisolone or
meloxicam
Cats 14 MCT, FOSCC, lymphoma,
various carcinomas
Clinical benefit: 57.1% Grade 1 neutropenia and GI
AE most common,
potential hepatotoxicity
reported
Cohort, retrospective 163
Single agent Cats 18 FISS No measurable clinical
response
Generally mild, grade 3
lymphopena and 4 ALT
elevation managed with
drug holidays
Experimental,
prospective
164
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Carboplatin,
piroxicam
Cat 1 Tracheal adenocarcinoma Survival: 755 d None reported Case report 165
Octreotide Cat 1 Gastrinoma Survival: 5 mo (euthanized) Anorexia, treatment
limiting
Case report 166
Single agent Binturong 1 Renal carcinoma Survival: 4 mo (euthanized) Mild inappetence Case report 184
Masatinib
Combination Species N Tumor Type(s) Clinical Effects Adverse Events Study Type Citation
Dogs 202 MCT Increased time to progression
75–118 d, more significant
in naive patients
Diarrhea, vomiting most common,
generally grades 1 and 2
Experimental, Double-blind,
randomized, placebo-controlled
phase III clinical trial
167
Dogs 132 MCT Increased survival compared
with placebo (617 vs 322d)
Not discussed Experimental, placebo-controlled
trial
168
Dogs 26 MCT ORR: 50%, response to
treatment predictive of
survival
Hepatic, proteinuria, hematologic
and GI, majority mild and self-
limiting
Experimental, placebo-
controlled trial
169
Dogs 10 CEL Overall clinical response:
70%
myelosuppression (mild),
vomiting/diarrhea (grade 4 in 1
dog), grade 3 anorexia,
petechiae, elevated ALT
Experimental, prospective
clinical trial
170
Dogs 39 MCT Overall clinical response:
82.1%
Elevated ALT (grade 3 or 4),
anemia (grade 3 or 4) and
vomiting (mild) most common
Observational, retrospective 171
Cats 20 — N/A proteinuria and neutropenia
noted, increased serum Cr, and
GI effects (mild)
Experimental, prospective,
randomized phase 1
clinical trial
172
Xenogeneic Melanoma Vaccines
Combination Species N Tumor Type(s) Clinical Effects Adverse Events Study Type Citation
Surgery, radiation,
 chemotherapy
Dog 9 Oral, nail/footpad,
intraocular
MST: 389 d Mild injection site
reactions
Experimental,
prospective (phase I);
antigen: huTyr
173
(continued on next page)
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Table 2
(continued )
Xenogeneic Melanoma Vaccines
Combination Species N Tumor Type(s) Clinical Effects Adverse Events Study Type Citation
Surgery, radiation,
 chemotherapy
Dog 170 Various MST (stage II–IV):
389 d (huTyr), 153
(muGP75), 224
(muTyr)
Mild pain on injection Experimental,
prospective (phase I);
antigens: huTry,
muTyr, muGP75
174
Surgery alone
 steroids
Dog 111 Oral Signficant improved
survival over
historical controls,
MST could not be
calculated
Mild injection site
reactions, mild pain
on injection
Experimental,
prospective (phase II);
antigen: huTyr
175
Amputation, radiation Dog 58 Digit MST: 476 d Mild, local pain on
injection, 9 dogs
Observational,
retrospective;
antigen: huTyr
176
Single agent or
radiation
Dog 45 Oral PFS (vaccinates): 199 d;
(nonvaccinates):
247 d; no
improvement in
survival
Not discussed Observational,
retrospective;
antigen: huTyr
177
Radiation, surgery Dog 32 Oral MST: 335 d None observed Observational,
retrospective;
antigen: huTyr
178
Surgical excision Dog 38 Oral, digit,
cutaneous
Oral: MST—26 mo;
Digit: MST—36 mo;
Other: 22 mo
None observed Observational,
retrospective;
antigen: huTyr
179
Surgery, chemotherapy,
radiation
Dog 11 Anal sac MST: 107 d None observed Observational,
retrospective;
antigen: huTyr
180
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Various chemotherapy,
radiation
Dog 69 Oral MST: 455 d Not specified, stated as
“minimal”
Observational,
retrospective;
antigen: huTyr
181
Various chemotherapy,
radiation
Cat 24 Oral, ocular/
periorbital,
dermal,
mucocutaneous,
lip, subcutaneous
Not evaluated Minimal, grades 1 and 2
anorexia, nausea, 2
cats grades 3 and 4
myelosuppression
Observational,
retrospective;
antigen: huTyr
182
Radiation, surgical
excision
Lion 1 Oral Complete response None observed Case report; antigen:
huTyr
196
Radiation, strontium African penguin 1 Nare 14-mo survival
(previous reported
mean of 7 mo)
None reported Case report; antigen:
huTyr
187
Clinical benefit: complete response, partial response, or stable disease.
Objective response rate (ORR): complete response, partial response.
Abbreviations: AE, adverse events; ALT, alanine transferase; ASAGACA, anal sac apocrine gland adenocarcinoma; CCNU, Lomustine; CEL, canine epitheliotropic
lymphoma; Cr, creatinine; CR, complete response; FISS, feline injection-site sarcoma; FOSCC, feline oral SCC; HNCA, head and neck carcinoma; HSA, hemangiosar-
coma; IFN, interferon; LSA, lymphosarcoma; MCT, mast cell tumor; MCT, mast cell tumor; MH, malignant histiocytosis; MLO, multilobulated osteochrondrosar-
coma; MMC, mixed mammary carcinoma; MST, median survival time; N/A, not reported; NCA, nasal carcinoma; OR, objective response; OS, overall survival;
OSA, osteosarcoma; OSCC, Oral Squamous Cell Carcinoma; PCA, prostatic carcinoma; PFS, progression-free survival; PLN, protein-losing nephropathy; STS, soft tis-
sue sarcoma; TC, thyroid carcinoma; Treg, regulatory T Cells; TTP, time to progression.
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Zehnder et al488The second is masitinib (Masivet), targeting primarily the mutated forms of the c-kit re-
ceptor, platelet-derived growth factor receptor, lymphocyte-specific kinase, Lck/Yes-
related protein, fibroblast growth factor 3, and focal adhesion kinase.183 It is being
researched in human oncology for the treatment of multiple cancer types (including GI
stromal tumors, pancreatic tumors, and melanoma). Masitinib was approved for use in
veterinary medicine for the treatment of nonresectable canine mast cell tumors and rep-
resented one of the only drugs approved for veterinary cancer patients that is also used in
clinical trials for human patients. There are no published reports ofmasitinib use in exotics
species. Masitinib, however, lost conditional approval from the Food and Drug Adminis-
tration on December 15, 2015, and it is no longer legal for this drug to be distributed in the
United States. It is still available, however, in the United Kingdom and other European
countries, according to the European Medicines Agency, as of October 2017.186
Tumor Vaccines
In addition to the tyrosine kinase inhibitors described previously, there is a vaccine
(Oncept; Merial, Duluth, Georgia) developed to target caninemelanoma that has been re-
ported in sporadic proceedings case reports in exotic species.187,188 This is a xenogeneic
(cross-species) vaccine that targetsanenzyme, tyrosinase, that isexpressed inmelanoma
cells. It is xenogeneic because it uses human tyrosinase to trigger an immune response to
canine tyrosinase in canine patients. It is the onlyUSDepartment of Agriculture–approved
cancervaccineapproved fordogs.The treatmentprotocol forcaninemelanoma involvesa
transdermal vaccine every 2 weeks for 4 treatments and then vaccine boosters every
6 months. The evidence for improved progression-free survival in dogs treated with vac-
cinescomparedwith traditional radiationandchemotherapyprotocols is inconclusiveand
it is unclear at this time that there is asignificant survival benefit foranimals treatedwith this
vaccine. Also, the expression of tyrosinase in caninemelanomas can be variable accord-
ing topublished reports.189Thevalueof this therapy for exotic species remains tobeseen,
and more studies are needed to determine its potential efficacy.
RADIATION THERAPY IN EXOTIC SPECIES
For patients with confirmed local disease where complete surgical resection is not
possible due to anatomic or other considerations, radiation therapy is a reasonable
therapeutic modality. The 2 major types of radiation are external beam and strontium
90, both of which have been reported in exotic species. When clinicians are consid-
ering radiation therapy, the authors strongly recommend consultation with a radiation
oncologist because there are frequent improvements in radiation oncology relating to
the ability to accurately map tumor tissue and spare normal tissue.190
External Beam Radiation
Two different types of external beam radiation can be distinguished—orthovoltage
and megavoltage radiation therapy. Each has its own characteristics, which render
them useable for different tumor types. Orthovoltage (x-rays of 150–500 kilovolt
[peak]) has lower energy and, therefore, lower penetration, making it more appropriate
for tumors of the skin and subcutaneous tissues. This type of radiation has a prefer-
ence for bone and the chances of late effects (necrosis) on bony tissues is high. Meg-
avoltage (photons >1 million MeV) is higher energy and effects build up in tissue. The
interaction of megavoltage rays with tissue is more predictable and this radiation type
is used in computerized radiation planning schemes. Advances in radiation planning
software and machine hardware allow for more contoured radiation plans, sparing
more normal tissue (Fig. 7).
Fig. 7. Intensity-modulated radiation therapy planning in a rabbit for thymoma. (Courtesy
of Tara Harrison, DVM, MPVM, Dipl. ACZM, Dipl. ACVPM, North Carolina State University.)
Update on Cancer Treatment in Exotics 489Tumors commonly treatedwith external beam radiation (in dogs andcats) include oral
tumors, in particular melanoma and SCC, nasal tumors (sarcomas, carcinomas, and
lymphomas), brain tumors, pituitary tumors, soft tissue sarcomas of the trunk and ex-
tremities, mast cell tumors, bone tumors (as part of multimodal therapy), and localized
lymphomas. Recent reviews14,21,191–193 have discussed the specific use of radiation in
exotic species. Clinically, tumor types treated with radiation in exotics include a myx-
oma in a goldfish191; papilloma,194 sarcoma,195 andSCC196 in reptiles; SCC,197,198 mel-
anoma,199 hemangiosarcoma,200 osteosarcoma,201 lymphoma,202 and fibrosarcoma in
birds203; thymoma,204 lymphoma, myeloma, seminoma, and nasal adenocarcinoma in
rabbits205–208; preputial tumors209; chordoma210; SCC211; lymphoma212; andadenocar-
cinoma in ferrets.213,214 In some cases, radiation can be used as a sole therapy, but it
may also be combined with surgery or chemotherapy (in particular intralesional chemo-
therapy), depending on the tumor type/location and patient constraints (size and pres-
ence of comorbidities). Certain large tumors that cannot be resected may be treated
with radiation to shrink them and make them more amenable to surgical resection.
Also, radiation may be used after a surgical resection if the resection was determined
to be incomplete on inspection of the margins.
Definitive versus palliative protocols
External beam radiation therapy can generally be broken into definitive and palliative pro-
tocols. The goal of definitive therapy is curative and involves an increased number of frac-
tions and may provide higher gray/fraction. Definitive radiation is generally pursued if a
patient is anticipated to live at least 1 year after therapy. These radiation protocols, how-
ever, may be associated with an increased risk of acute radiation side effects due to the
increased number of fractions. Patients with an overall poor quality of life or a shorter life
expectancy (generally <6 months) may be more appropriately treated with palliative pro-
tocols. These protocols have fewer fractions and have less frequent acute side effects.
Side effects and tolerance
The side effects of external beam radiation are divided into acute and chronic side ef-
fects. Acute side effects are related to the number of fractions provided as well as the
area of the body being treated. Acute side effects may include mucositis, desquama-
tion (dry or moist), and keratitis. Late radiation effects in mammals can include necro-
sis, fibrosis, nonhealing ulceration, central nervous system damage, and blindness,
depending on the normal tissues being irradiated.215 Although rare (1%–2% of cases)
in humans and dogs, new tumors have been reported to develop at the site of radiation
therapy. This has not yet been reported in avian oncology, but, given the long life span
Zehnder et al490of certain avian species, patients treated with radiation should be monitored for devel-
opment of tumors at previous treatment sites.
The radiation tolerance of normal tissues in many species is not well defined and can
be dramatically higher in some avian species. Quail and chickens are less radiosensitive
compared with other animals, such as sheep, cattle, and swine, when whole-body irra-
diation effects on bone marrow are examined.216–218 A study examined the tolerance
dose of cutaneous and mucosal tissues in ring-necked parakeets (Psittacula krameri)
for external beam megavoltage radiation and revealed minimal radiation-induced
epidermal histologic changes in the high-dose group receiving 72 Gy in 4-Gy frac-
tions.219 A more recent study in macaws revealed that radiation delivered to the sinuses
did not reach intended doses.220 This implies that higher doses of radiation may be
needed to produce equivalent response in avian patients compared with mammals,
although the radiosensitivity of avian tumors has not yet been investigated. As in birds,
studies examining the effects of radiation in other exotic species are mostly designed to
effects of radiation contamination and not treatment efficacy.14,21,191–193
Strontium 90
Strontium 90 has specific indications for superficial tumors with less than 2 mm of depth.
The level of radiation delivered decreases dramatically after 2 mm to 3 mm, so tumor
staging is critical prior to choosing this modality. The circular area that can be treated
with a strontium probe is approximately 8 mm and treated areas are arranged so they
overlap to cover the entire tumor area. Common indications for strontium- 90 therapy
include uropygial SCCs in birds, small tumors on the pinnal margin or nasal planum,
and other superficial skin tumors as well as treating a tumor bed postexcision if there is
concern regarding residual disease. Side effects of strontium 90 therapy are rare in the
cases of it being been used and include local skin effects, such as alopecia, crusting, pru-
ritus, leukotrichia, and thinning and depigmentation of the skin reported in cats.221 Side
effects in exotics have not been documented to the authors’ knowledge.OTHER/MISCELLANEOUS THERAPY TYPES
Hormonal/Steroidal Therapies
The most used hormones in veterinary medicine are corticosteroids, which are helpful
in certain specific tumor types, including mast cell tumors, lymphomas, and lymphoid
leukemias.222 It is believed that steroids cause altered cellular transport of nutrients,
apoptosis, and terminal differentiation in cancer cells. The effects are generally short
lived, however, and there is concern of inducing multidrug resistance to chemothera-
peutics in lymphoid cancers. Certain species are particularly susceptible to immuno-
suppression and secondary infection from the use of steroids, including birds and
many small mammals, whereas others tolerate steroid therapy with few side effects
(eg, ferrets). For steroid-sensitive species, prophylactic antibiotics and antifungals
may be necessary when steroids are used as part of a cancer treatment protocol
and patients should be closely monitored for signs of infection. Tamoxifen administra-
tion has not been evaluated for efficacy in cases of ovarian carcinoma, but antiestro-
genic activity was suggested in 1 drug trial in budgerigars.223 Gonadotropin-releasing
hormone agonists (ie, leuprolide acetate) have been reportedly effective for ovarian
carcinoma in birds in case reports in a small number of birds.224,225
Cryotherapy
Cryotherapy is reported infrequently in the exotic tumor literature.132 It is a local ther-
apy using extreme cold produced by liquid nitrogen or argon gas and is indicated in
Update on Cancer Treatment in Exotics 491treating small, local lesions or residual disease postsurgical resection. Repeated treat-
ments may be needed to achieve tumor control226 and patients should be monitored
closely for recurrence. Treatment areas should be monitored for any related skin ef-
fects, but such side effects are rarely reported. Care should be taken if used over areas
of bone because it can cause necrosis.
Other Types of Therapy
Other therapy types that have been reported in exotic species include photother-
apy, hyperthermia, immunotherapy, nonsteroidal therapy, antiangiogenic agents,
metronomic chemotherapy, electrochemotherapy, and complementary and alter-
native therapies, and these have been discussed in recent reviews.13,20,227,228
Because they have been recently reviewed and there are only sparse data on
efficacy of these therapies, they are not discussed in depth in this review. A brief
review of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in anticancer
therapies is provided.
Epidemiologic studies in man have demonstrated a protective effect of chronic
aspirin intake in the incidence of colorectal cancer.229 Anti-inflammatory drugs to
slow or stop tumor growth have shown promise in several animal model systems and
clinical cancer cases. A majority of NSAIDs inhibit the isoforms of cyclooxygenase
(COX-1 and COX-2) or are selective for 1 isoform. The NSAID piroxicam has activity
against a variety of tumors in humans and dogs. Piroxicam is used in the treatment
of transitional cell carcinomas (TCCs) of the urinary bladder and urethra in dogs and
has also shown benefit in treatment of some SCCs and mammary adenocarcinomas.
Canine patients receiving piroxicam or meloxicam seem to have an improved quality
of life, with increased activity and alertness reported by owners.229 Oral piroxicam
has uncommonly been associated with GI ulceration and renal papillary necrosis in
dogs. Meloxicam or other selective COX-2 inhibitors may be safer alternatives to pirox-
icam in the treatment of cancer, because they may reduce possible GI side effects due
to increased COX-2 selectivity, but their effectiveness as an anticancer therapy is less
well studied.TREATMENT STRATEGIES FOR TUMORS
Often, deciding on the appropriate treatment regimen for a particular patient with
cancer can be bewildering. Some general principles remain unchanged, regardless
of species, and some are highly species specific. No 1 book chapter or journal article
can address every clinical situation and the authors strongly recommend close
consultation with a boarded veterinary oncologist to make individual-level treatment
decisions.
General considerations that apply to every cancer patient are the resectability of the
primary tumor, the presence of multiple or distant lesions, technical or logistical con-
cerns, and patient comorbidities. Exotic practitioners are limited by some additional
concerns, because basic issues like obtaining repeated, dedicated venous access
may not be possible. Exotic patients can be very small, and they generally require
repeated anesthetic episodes for treatments like chemotherapy, which poses more
of a risk than for dogs and cats, which do not require multiple anesthetic episodes.
Additionally, many exotic species may hide underlying illnesses and may be more sus-
ceptible to immunosuppressive effects of corticosteroids, a commonly component of
treatment of dogs and cats with certain lymphoid tumors. Clinicians need to work
closely with owners to make sure they understand that nearly all the treatment recom-
mendations the authors make for exotic patients are extrapolated from treatments
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the effectiveness of cancer therapy in exotic species. It is important to discuss with
owners that necropsies at the time of death may provide additional information to
expand the knowledge of behaviors of neoplasia in exotic species.
For every patient, the first question to ask of a diagnosed tumor is whether or not it is
surgically resectable (Fig. 8). The first surgery represents the best chance of a cure
and the surgeon needs to ask the following questions before planning a procedure:
What is the histologic type and (to your best knowledge) the stage and grade of the
cancer? What is the potential for local versus metastatic spread? Can a complete
excision be performed and what are the cosmetic and functional trade-offs? and
Are there any alternative options or plans for combined radiation or chemotherapy?
This is the time when appropriate and interpretable diagnostics are key, to determine
the true extent of the tumor and whether there is any evidence of distant disease
because this would negate the reason for an extensive local surgical resection. Spe-
cial considerations for exotic species include different healing capacities of skin types
(mammal vs avian vs reptile) as well as elasticities for planning wound closures.
Different species also tolerate different levels of surgical manipulations (eg, amputa-
tions) and knowledge of the normal anatomy and how well species can adapt to sig-
nificant surgical alterations. Additionally, the planned “use” of the animal may guide
therapy, in terms of whether this is a wild animal that needs to be released or a pet
that can live with some level of disability.
For tumors where it is determined that surgical excision is feasible and indicated,
basic oncological surgical principles apply. Appropriate surgical margins are not well
defined for exotic species, and guidelines should be taken from histologically similar tu-
mors in dogs, cats, or humans, where appropriate. The authors refer readers to recent
excellent reviews on the topic and appropriate book chapters.230,231 If surgicalFig. 8. Decision tree for exotic patients with neoplastic disease. a Recommended histology
be performed on all excised tumors. b If tumor was high grade or there are metastases,
adjunctive chemotherapy is indicated. c May be appropriate for lesions greater than
2 mm in depth depending on location and proximity to nearby vital structures. (Adapted
from Zehnder A, Graham J, Reavill DR, et al. Neoplastic diseases in avian species. In: Speer
B, editor. Current therapy in avian medicine and surgery. 1st edition. St Louis [MO]: Elsevier;
2016. p. 118; with permission.)
Update on Cancer Treatment in Exotics 493resection is not an option, if there is already distant disease detected, or if surgery is
attempted but margins are not clean on histologic examination, additional therapies
are determined by the lesion size, lesion depth, and presence of distant disease. For
small local lesions or residual superficial tumor beds postsurgery, recommended treat-
ments include intralesional chemotherapy, cryotherapy, or strontium 90 radiation. As
discussed previously, strontium 90 is only important for lesions less than 2mm in depth.
For deeper but still local lesions, external beam radiation is considered more appro-
priate and the type and treatment protocol are guided by the histology. For distant le-
sions, chemotherapy or use of newer, molecularly targeted agents is appropriate.
Again, the agent and protocol are guided by the type of disease as well as consultations
with medical oncologists. The authors have attempted to discuss the indications for
different chemotherapies as well as for newer molecular agents as a guide for clinicians.
There is insufficient primary literature in exotic species, however, to be able to predict
treatment efficacy or necessarily predict adverse events for specific patients, and
owners need to be aware of these limitations.NUTRITION/SUPPORTIVE CARE FOR EXOTIC CANCER PATIENTS
Appropriate nutritional support is vital for cancer patients. Cancer cachexia (CC) is a
well-known phenomenon that has been described in both human and veterinary spe-
cies.232 CC causes significant changes in nutrient metabolism, leading to weight loss
and muscle atrophy. CC is typically progressive and can have a significant impact on
both length and quality of life if it is not appropriately managed.233 Although no studies
have been published on whether CC occurs in avian and reptile species, it is probable
that they experience a similar syndrome, because progression of neoplasia in exotic
species usually closely mirrors progression in other species.
Recommendations for management of CC include feeding a highly digestible diet
that is limited in simple carbohydrates, contains moderate amounts of highly bioavail-
able amino acids, and contains increased amounts of fat. Supplementing the diet with
omega-3 polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic
acid, may be protective against some of the common metabolic abnormalities asso-
ciated with CC and may improve response to treatment.234 Omega-3 polyunsaturated
fatty acids can be generally recommended as a healthy supplement for avian and
other exotic patients, because they are also beneficial for cardiovascular, skeletal,
and neurologic health.235 Adequate insoluble fiber intake can improve GI health and
promote normal GI flora, which may benefit patients undergoing cancer therapy.236
Unfortunately, there is no published information on the association of different die-
tary factors with cancer in exotic species. The impact of vitamins, minerals, and micro-
nutrients on cancer risk and treatment has been extensively discussed in the human
literature.237 Carotenoids, selenium, folic acid, and vitamins A, C, E, and D have all
been linked in certain studies to a reduction in cancer risk; however, many studies
have produced conflicting information, and there is currently limited consensus on
their correlation to cancer development.238
Regardless of which dietary supplements are elected for use in a cancer patient (if any),
the patient must eat to benefit from nutritional support. The use of appetite stimulants,
such as vitamin B complex or benzodiazepines, may be helpful.239–241 Warming the
food prior to offering it to a patient and decreasing stress in the surrounding environment
may improve food acceptance. Appropriate medical management of pain and nausea is
an extremely important factor. Metoclopramide may be used to help decrease nausea,
improve appetite, and improve normal GI motility.242 The efficacy and safety of other anti-
nausea medications have not been critically evaluated in birds and other exotic species.
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ingluviotomy tube can be performed for long-term nutritional management. There
are a variety of commercially available liquid critical care diets for exotic species
that can be used for nutritional supplementation via these methods.PATIENT MONITORING AND SIDE EFFECTS
In exotic animal practice, there is a lack of standardization for quantifying patient out-
comes as well as adverse effects. This lack of consistency and quantitative patient in-
formation greatly hinders the ability to combine cases from different institutions as well
as to assemble larger case series to analyze population-level data for different types of
cancers. Within canine and feline oncology, as well as within human oncology, there
are extensive tools for this type of patient monitoring and these should be adapted,
as appropriate, for exotic patients. It is crucial for clinicians to convey to owners the
importance of regular rechecks, even when patients are apparently doing well, and
to inform veterinarians when patients die at home. Owners should be encouraged
to allow necropsy whenever feasible, because it may be hard to know otherwise if
therapies are truly effective or if there are subclinical side effects from therapy that
may not otherwise be diagnosed.
Adverse Events
There is a range of adverse events that may occur secondary to chemotherapy admin-
istration, radiation treatment, or other cancer therapies. For patients undergoing
chemotherapy, CBCs should be monitored weekly to biweekly, and treatment should
be delayed if the heterophil/neutrophil count is too low. Based on information obtained
in dogs and cats,119,243 it is recommended that treatment should be delayed in pa-
tients with a heterophil (in birds and reptiles) or neutrophil (in mammals) counts less
than 2000 cells/mL if a drug that is generally considered myelosuppressive is sched-
uled. If the drug is not considered myelosuppressive, it may be possible to administer
therapy as long as the heterophil/neutrophil count is 1500 cells/mL. A conservative rule
is to administer appropriate antimicrobial therapy to any avian or exotic patients with a
heterophil count below 2000 cells/mL or less than 25% of the normal reference range
for the species in question.
The Veterinary Cooperative Oncology Group (VCOG) has established common ter-
minology criteria for adverse events after chemotherapy or biological antineoplastic
therapy in dogs and cats.184 These documents define an adverse event as “any unfa-
vorable and unintended sign, clinical sign, or disease temporally associated with the
use of a medical treatment that may or may not be considered related to the medical
treatment.” Adverse events are categorized by different body systems with a separate
category for clinical pathology. There is a grading scale that quantifies the severity of
the observed effects. Generally, grade 1 is mild and may be subclinical, grade 2 is
moderate, grade 3 is severe, grade 4 is life-threatening, and grade 5 is death. Adverse
events in exotic species being treated for cancer should be recorded and can be
based on this information. A modified table for avian species is published in the recent
review of avian oncology by 2 of the authors and the same authors are developing a
more general version appropriate for additional exotic species.13 It is important for cli-
nicians to understand that they do not necessarily need to work out if the adverse
event is a direct consequence of a treatment. For patients treated with combinations
of therapies, it may not be clear which treatment is responsible for an observed event
or an event may be due to an underlying disease process. It is important, however, to
record any adverse events that are noted and make it clear in the medical record the
Update on Cancer Treatment in Exotics 495doses, dosing intervals, and periods of time when treatments are administered so that
cases can be accurately analyzed retrospectively for potential adverse events.Assessing Response to Therapy
Human oncologists use Response Evaluation Criteria in Solid Tumors (RECIST) to
objectively monitor primary tumors (target lesions) and lymph nodes and provide a
standardized way to compare outcomes across multiple clinical trials and patient pop-
ulations. These criteria received a major update in 2009 and are used in a majority of
clinical trials.244 The VCOG published an adapted version of these criteria for canine
solid tumors in 2015.245 Even in dog and cat oncology, these standards are not well
established. There are a few basic guidelines, however, that clinicians can adopt
into their practice to make their patient assessments more quantitative and allow ac-
curate patient assessments over time.
Basic RECIST guidelines address the following points: baseline tumor measure-
ments, methods of tumor assessments, evaluation of tumor response, and definitions
of progression-free survival. Accurate, baseline tumor assessments (Fig. 9) are the key
to objectively evaluating a patient’s later response to therapy. It is recommended that
measurements be taken as close as possible to the initiation of therapy. Lesions that
are larger than 10 mm should be followed either with caliper measurements (for cuta-
neous lesions) or imaging modalities for internal lesions (where feasible). Ultrasonog-
raphy is not recommended for repeated tumor assessments if other options are
available. Due to the imprecise nature of radiographs and ultrasound, only lesions
greater than 20 mm should be routinely monitored using these modalities. If patients
have PET scans, they can be used to monitor response but not for accurate lesion
measurements. Consistency is also important when tracking lesions. If caliper mea-
surements are used, it is advisable for the same people to obtain those measurements
at subsequent visits. CT scans are preferred over radiographs; however, these are not
always feasible due to concerns over cost and longer anesthesia times. If ultrasound
scans are used to follow lesions, it is important to use the same radiologist for the
scans and use previous images to guide acquisition of new images so they are ob-
tained in the same plane. In evaluation of patient response, clinicians should attempt
to quantitate a patient’s overall tumor burden in all measurable lesions. The longest
diameters of target lesions (those that are measured repeatedly over time) are
summed to obtain the “baseline sum diameters.” This is the reference for assessing
patient response.Fig. 9. Using calipers to measures a patagial SCC in a cockatiel prior to chemotherapy
administration.
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response, partial response, progressive disease, and stable disease. Complete
response describes the complete disappearance of all target (measured) lesions. Par-
tial response describes at least a 30% reduction in the sum of diameters of target le-
sions (using the baseline sum as a reference). Progressive disease describes the
appearance of new lesions or a 20% or greater increase in the sum of diameters of
target lesions. Stable disease describes less than 30% decrease or less than 20% in-
crease in tumor burden. There are additional details regarding nontarget or nonmea-
surable lesions and the authors suggest reading the VCOG consensus document for
more information.245
FUTURE DIRECTIONS
A recurring theme in every article and book chapter relating to cancer therapeutics in
exotic and zoologic species is the extreme lack of remotely sufficient published knowl-
edge regarding basic tenets of cancer biology and treatment of these species. Clini-
cians and researchers often are essentially guessing at the best therapies from 1, 2,
or, in some cases, no published reports and every patient is an n of 1, particularly
for more rare tumors in rarer species. The questions that remain to be asked are
many. Do histologically similar tumors in these species behave like their counterparts
in humans, dogs, or cats? Are the underlying genetic or molecular alterations similar
and how do they affect patient prognosis? How long will a certain animal live with a
particular tumor without treatments and which treatments actually prolong life? How
do clinicians and researchers appropriately extrapolate therapies across species
with widely different metabolisms, different dose tolerances, and potential species-
specific toxicities? How can the level of case documentation, tumor quantification.
and outcome and side effects reporting be improved to be able to better integrate clin-
ical cases with those from other species?
How to do this is by better communicating cases to others and by accumulating
cases in a central location with standardized clinical information, to start drawing sta-
tistically valid conclusions from clinical data. The Exotic Species Cancer Research Alli-
ance is one such effort and has built a repository for clinical cases (Exotic Tumor
Database) to try to answer some of these questions. Information regarding this effort
is at www.escra.org, where there are resources to help clinicians find and enter their
cases for the collective good of exotic clinicians and their patients.
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